Amgen is planning to push its olpasiran candidate for reducing lipoprotein(a) into phase 3 as quickly as possible as it tries to catch up with rival programmes at Novartis. The US biotech has just ...

Amgen will now move ahead with a phase 2 programme for AMG 133, as it tries to enter a weight-loss category that has been transformed by the approval of Novo Nordisk’s once-weekly GLP-1 agonist ...

Dow Jones member Verizon is climbing despite the overall market correction. Amgen's weight loss drug is helping it to outperform the broad market. The NASDAQ opened more than 2% lower on Monday ...

Want to know when Jackpocket goes live in your state? Sign up to reserve your free lotto ticket. Did you play the Mega Millions? Check the winning numbers for the Tuesday, March 11, 2025 drawing ...

Ukraine has said it is ready to accept an immediate 30-day ceasefire with Russia proposed by the US, after a... Armed militants in Pakistan’s Balochistan region have attacked a train carrying more ...

Tuesday 11th March, 2025 The JVP-led NPP government engages in smoke and mirrors with the same finesse as a professional illusionist, slipping away from its unfulfilled... Saturday 8th March, 2025 ...

For the third time, Newsweek, in collaboration with market research partner Statista, recognizes the Most Trustworthy Companies in America in 23 industries according to U.S. residents' evaluations ...

Xtrackers S&P 500 Swap UCITS ETF - 1C USD ACC 23% SPDR S&P 500 UCITS ETF - USD DIS 23% ...

Biosimilar Litigations include litigations relating to biosimilar/follow-on products of CDER-listed reference products. Litigations between biosimilar applicants/manufacturers and reference ...

Pre-Market: 8:33:11 a.m. EDT Loading Chart for AMGN ...